• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Sciences >Evaluation of Plasma Endothelin-1 and Serum Inflammatory Markers in Patients with Diabetic Retinopathy
【24h】

Evaluation of Plasma Endothelin-1 and Serum Inflammatory Markers in Patients with Diabetic Retinopathy

机译：糖尿病视网膜病变患者血浆内皮素-1和血清炎症标志物的评价

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hyperglycemia has been identified as the major factor for the development of diabetic microvascular complication including retinopathy. Increased expression of Endothelin -1 (ET-1) is associated with diabetic retinopathy and vasculopathy, although the molecular explanation has not been defined. The study was conducted on 55 patients suffering from type 2 diabetes attending the Retina Clinic of Ophthalmology, Research Institute of Ophthalmology, seeking advice as regard eye complications of diabetes. The patients were divided into three groups: Group I included 15 patients who had no retinopathy, Group II including 20 patients with non-proliferative diabetic retinopathy of varying severity and Group III including 20 patients with proliferative diabetic retinopathy. Beside 20 healthy, age and sex matched subjects as a control group. The aim of this study was to examine whether ET-1 plays a role in the progression of diabetic retinopathy in cooperation with the other inflammatory markers. Also to detect the relationship between the stages of diabetic retinopathy and the inflammatory activity by measuring serum IL-6, CRP, haptoglobin and alpha-1 antitrypsin as markers of inflammation. All patients were subjected to the following: detection of plasma levels of glucose and ET-1, serum levels of IL-6, CRP, haptoglobin, α-1 antitrypsin, ALT and AST). The results showed that, the plasma level of ET-1 was increased significantly in-Group II and Group III as compared to the control group and the highest level was detected in-Group III. While, the other inflammatory markers (IL-6, CRP, haptoglobin and α-1 antitrypsin) its serum levels were increased significantly as compared to the control group. There were statistically significant positive correlation (p -1 with sensitivity 80% and specificity of 90%, while in Group II the best cut off value was 1.51 pg mL-1 with sensitivity 95% and specificity of 100% and in Group III the best cut off value was 1.63 pg mL-1 with sensitivity 100% and specificity of 100%. The positive and the negative predictive values in the three studied groups were (90.9 and 82.6, 100 and 95.24 and 100 and 100%, respectively). In conclusion, ET-1 plays some role in the development of retinopathy in diabetic patients in cooperation with the markers of inflammation and may be helpful to predict the presence of proliferative diabetic retinopathy in patients with diabetes mellitus. Thus identifying and treating markers for vascular disease in diabetes is significant in preventing long-term disabilities and containing health care costs, also it recommended to maintain normal blood glucose levels in diabetes patients, as blood glucose that is elevated for several years is a major factor in the development and progression of microvascular disease complications.
机译：高血糖已被确定为糖尿病性微血管并发症（包括视网膜病变）发展的主要因素。内皮素-1（ET-1）的表达增加与糖尿病性视网膜病变和血管病变有关，尽管尚无分子解释。该研究是对55名2型糖尿病患者进行的研究，这些患者在眼科研究所眼科视网膜诊所接受了有关糖尿病眼部并发症的咨询。将患者分为三组：第一组包括15例无视网膜病变的患者，第二组包括20例严重程度不同的非增生性糖尿病视网膜病变的患者，第三组包括20例增生性糖尿病视网膜病变的患者。除了20名健康，年龄和性别匹配的受试者作为对照组。这项研究的目的是检查ET-1是否与其他炎症标记物一起在糖尿病性视网膜病变的进展中起作用。还通过测量血清IL-6，CRP，触珠蛋白和α-1抗胰蛋白酶作为炎症指标来检测糖尿病性视网膜病变的阶段与炎症活性之间的关系。所有患者均接受以下检查：检测血浆葡萄糖和ET-1水平，血清IL-6，CRP，触珠蛋白，α-1抗胰蛋白酶，ALT和AST水平。结果表明，与对照组相比，第二组和第三组的血浆ET-1水平明显升高，第三组的血浆ET-1水平最高。而其他炎症标志物（IL-6，CRP，触珠蛋白和α-1抗胰蛋白酶）的血清水平与对照组相比则明显升高。在统计学上有显着正相关（p -1 ，敏感性为80％，特异性为90％，而在第二组中，最佳截止值是1.51 pg mL -1 ，敏感性为95％特异性为100％，第三组的最佳临界值为1.63 pg mL -1 ，敏感性为100％，特异性为100％，三个研究组的阳性和阴性预测值分别为（分别为90.9和82.6、100和95.24以及100和100％。）总之，ET-1在糖尿病患者视网膜病变的发展中与炎症标志物协同起作用，可能有助于预测糖尿病的发生。糖尿病患者的增生性糖尿病性视网膜病，因此，识别和治疗糖尿病血管疾病的标志物对于预防长期残疾和控制医疗费用具有重要意义，还建议维持糖尿病患者的正常血糖水平，例如血糖升高数年是微血管疾病并发症发生和发展的主要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号